Valuation : Memphasys Limited

Market Cap 15.44M 11.07M 9.54M 9.03M 8.19M 15.36M 1.06B 107M 41.25M 538M 41.58M 40.67M 1.7B P/E 2025
-1.57x
P/E 2026 -3.94x
Enterprise Value 18.5M 13.27M 11.43M 10.83M 9.81M 18.41M 1.27B 129M 49.44M 645M 49.84M 48.74M 2.04B EV / Sales 2025
24,365,123x
EV / Sales 2026 35,157,730x
Free-Float
61.3%
Yield 2025 *
-
Yield 2026 -
1 day-16.67%
1 week-16.67%
1 month-16.67%
3 months-16.67%
6 months-16.67%
Current year-28.57%
1 week 0
Extreme 0.005
0.01
1 month 0
Extreme 0.005
0.01
Current year 0
Extreme 0.004
0.01
1 year 0
Extreme 0.002999
0.01
3 years 0
Extreme 0.002999
0.01
5 years 0
Extreme 0.002999
0.12
10 years 0
Extreme 0.002999
0.16
Manager TitleAgeSince
Director of Finance/CFO - -
Chief Tech/Sci/R&D Officer - 01/07/2021
Chief Operating Officer - 24/04/2023
Director TitleAgeSince
Director/Board Member - 07/06/2018
Director/Board Member - 20/10/2025
Chairman - 19/05/2026
Date Insider Type Main position Quantity % Market Cap. Importance
02/01/23 Buy

Director

1,400,000 0.1459%
02/01/23 Buy

Chief Executive Officer

392,500 0.0409%
24/01/22 Sell

Director

1,350,000 0.1704%
Change 5-day change 1-year change 3-year change Capi.($)
-16.67%-16.67%0.00%-61.53% 11.07M
+1.10%-0.65%+24.10%+18.43% 225B
-0.19%-3.62%+2.55%-20.00% 141B
+2.41%+0.67%-19.02%+22.09% 130B
-0.28%-10.08%-58.81%-21.22% 62.29B
-2.77%-6.15%+8.15%+12.69% 48.63B
-0.49%-1.97%-20.35%-15.53% 49.39B
+2.66%-2.61%+15.94%+29.91% 41.42B
+1.67%-0.25%+35.01%+55.09% 40.12B
-0.60%-4.41%-20.52%+44.06% 31.23B
Average -1.31%-4.75%-3.29%+6.40% 76.97B
Weighted average by Cap. +0.52%-2.50%+0.60%+9.84%

Financials

2025 2026
Net sales 0.53 0.38 0.33 0.31 0.28 0.52 36.1 3.66 1.41 18.37 1.42 1.39 58.04 0.66 0.47 0.41 0.38 0.35 0.65 45.08 4.57 1.76 22.94 1.77 1.73 72.48
Net income -5.04M -3.61M -3.11M -2.95M -2.67M -5.01M -345M -35.02M -13.47M -176M -13.57M -13.28M -555M -4.1M -2.94M -2.54M -2.4M -2.18M -4.08M -281M -28.52M -10.97M -143M -11.05M -10.81M -452M
Net Debt 4.9M 3.52M 3.03M 2.87M 2.6M 4.88M 336M 34.08M 13.11M 171M 13.21M 12.92M 540M 3.07M 2.2M 1.89M 1.79M 1.63M 3.05M 210M 21.3M 8.19M 107M 8.26M 8.08M 338M
Logo Memphasys Limited
Memphasys Limited is an Australia-based reproductive biotechnology company. The Company is engaged in developing medical devices, diagnostics, and media with application to assisted reproductive technology (ART) in humans and animals. The Company's product pipeline includes Felix, RoXsta, and AI-Port. Its advanced product, the Felix System, is a patented automated device for quickly and gently separating sperm from a semen sample for use in ART procedures. The Felix device consists of two main components: a console, which supplies electrical power, and a sterile disposable cartridge for sperm isolation and selection. RoXsta is an in-vitro diagnostic device that assesses semen and other bodily fluids for oxidative stress load. RoXsta also has an application as part of a suite of products that can support the animal industry. AI-Port has been developed for the purpose of maintaining the viability of livestock semen for up to seven days at a temperature range of 22 - 25 degrees Celsius.
Employees
24
Date Price Change Volume
11/09/26 A$0.005000 -16.67% 315,394
10/09/26 A$0.006000 0.00% 1,036,666
09/09/26 A$0.006000 0.00% 1,538,693
08/09/26 A$0.006000 -7.69% 4,255,319
07/09/26 A$0.006500 +8.33% 314,571
40% Discount: Identify Tomorrow's Best Investments With The Best Subscriber-Only Tools!
d
:
:
SEIZE THE OFFER!